Affiliation:
1. Départment de la Recherche Médicale, Commissariat à l'Energie Atomique, Fontenay aux Roses, Paris, France.
Abstract
To test the efficacy of a new amphotericin B derivative, MS-8209, in delaying scrapie, hamsters were infected intracerebrally with the 263K scrapie agent and treated with MS-8209 either early in the course of the disease or continuously. The results show that (i) all treatments lengthened the incubation period of hamster scrapie, (ii) continuous treatment with MS-8209 doubled the length of the incubation period compared with that observed in infected, untreated animals, and (iii) all treatments delayed the accumulation of a proteinase-resistant prion protein and glial fibrillary acidic protein in the brain. These findings suggest that MS-8209 is a powerful tool for investigating the pathogenesis of transmissible subacute spongiform encephalopathies.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference15 articles.
1. Chemotherapeutic trials in experimental slow virus disease;Amyx H.;Neurology,1984
2. Identification of a protein that purifies with the scrapie prion;Bolton D. C.;Science,1982
3. A therapeutic panorama of the spongiform encephalopathies;Brown P.;Antivir. Chem. Chemother.,1990
4. Pharmacological studies of a new derivative of amphotericin-B, MS-8209, in mouse and hamster scrapie;Demaimay R.;J. Gen. Virol.,1994
5. Hyperproduction de la protéine gliofibrillaire acide (GFAP) au cours de l'évolution de la tremblante expérimentale de la souris;Dormont D.;C. R. Acad. Sci.,1981
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献